Table 1.
ADT+ (n = 78) | ADT− (n = 99) | CA− (n = 108) | ADT+ vs. ADT− | ADT+ vs. CA− | ADT+ vs. All Controls | |
---|---|---|---|---|---|---|
| ||||||
Characteristic | Mean (SD) | Mean (SD) | Mean (SD) | t (p) | t (p) | t (p) |
| ||||||
Age, years | 68.49 (8.52) | 67.71 (7.46) | 67.80 (11.93) | 0.65 (.52) | 0.46 (.65) | 0.57 (.57) |
| ||||||
Years since diagnosis | 4.01 (5.08) | 4.69 (4.53) | - | −0.91 (.37) | - | - |
| ||||||
Body mass index, kg/m2 | 28.29 (4.04) | 29.30 (4.12) | 29.65 (5.19) | −1.42 (.16) | −1.73 (.09) | −1.70 (.09) |
| ||||||
Comorbidity index score | 2.86 (1.11) | 2.38 (0.80) | 2.68 (1.06) | 3.17 (.002) | 1.13 (.26) | 2.43 (.02) |
| ||||||
Characteristic | No. (%) | No. (%) | No. (%) | χ2 (p) | χ2 (p) | χ2 (p) |
| ||||||
Education, years | 7.32 (.03) | 8.47 (.01) | 10.69 (.005) | |||
≤ 12 | 32 (41%) | 22 (22%) | 23 (21%) | |||
13 – 16 | 36 (46%) | 59 (60%) | 67 (62%) | |||
≥ 17 | 10 (13%) | 18 (18%) | 18 (17%) | |||
| ||||||
Race | 2.42 (.12) | 4.10 (.04) | 4.68 (.03) | |||
White | 68 (87%) | 93 (94%) | 103 (95%) | |||
Nonwhite | 10 (13%) | 6 (6%) | 5 (5%) | |||
| ||||||
Ethnicity | (.99) | (.53) | (.99) | |||
Non-Hispanic | 74 (95%) | 95 (96%) | 101 (94%) | |||
Hispanic | 3 (4%) | 3 (3%) | 7 (6%) | |||
Missing | 1 (1%) | 1 (1%) | 0 (0%) | |||
| ||||||
Gleason score | (< .001) | - | - | |||
4–6 | 12 (15%) | 31 (31%) | - | |||
7 | 17 (22%) | 26 (26%) | - | |||
8 | 18 (23%) | 2 (2%) | - | |||
9–10 | 8 (10%) | 0 (0%) | - | |||
Missing | 23 (30%) | 40 (40%) | - |
Note. ADT+ = prostate cancer patients treated with ADT; ADT− = prostate cancer patients not treated with ADT; CA− = men with no history of prostate cancer; SD = standard deviation. p values calculated using t-tests for continuous variables and χ2 tests or Fisher’s exact tests for categorical variables. Missing values were excluded from analyses. In analyses with cell sizes ≤ 5, p values were calculated using Fisher’s exact test which yields no test statistic.